Mice treated with a compound developed at ETH Zurich grew fewer gray hairs as they aged — one signal from a study examining why Alzheimer’s disease destroys nerve cells and whether a single enzyme, quietly misbehaving inside the brain, might be driving more of that destruction than previously recognized.
The enzyme is called GRK2 (G-protein-coupled receptor kinase 2). In healthy cells, it does unglamorous but vital work: helping cells read incoming signals, manage stress, and adapt to demands placed on them. The trouble begins when it stops functioning. Cells can chemically switch GRK2 off, producing an inactive version that accumulates and then starts clumping together in ways that damage the structures cells rely on most for energy.
The findings were published in the journal Cell Reports Medicine. The lead researcher is Ursula Quitterer, Professor of Molecular Pharmacology at ETH Zurich. The compound, known as “Compound 10,” is the result of nearly two decades of work. The findings have not yet been tested in humans.
Where the Research Began
The research began almost 20 years ago when Quitterer received brain tissue samples collected during tumor surgeries at Ain Shams University Hospital in Cairo. The samples came from both people with dementia and individuals without the condition. Those samples held the first clue.
Two forms of the enzyme GRK2 occur in cells: a normal, functional form and a form that has been inactivated by cellular metabolism. Quitterer and her team found that the inactivated form occurs in large quantities in the brain tissue of dementia patients. They were able to demonstrate the same pattern in a mouse model for Alzheimer’s disease.
As Quitterer explained in the ETH Zurich release, “It took so long simply because everything takes so long in Alzheimer’s research.” The lengthy timeline reflects the necessity of watching animals progress through the full arc of neurodegeneration before drawing meaningful conclusions about what slowed it.
The Enzyme That Turns on Itself
Inactive GRK2 does not simply shut down and become harmless. It forms abnormal clumps inside brain cells, and those clumps collect on mitochondria — the structures that produce much of the energy cells need to function. According to Quitterer, “The GRK2 aggregates block the pores of the mitochondria, reducing the amount of energy they can supply and leading to a situation of stress inside the cells.”
In mouse experiments, the researchers also found that inactive GRK2 promotes the production of amyloid beta, a protein that accumulates in the brains of people with Alzheimer’s disease. Amyloid beta places additional stress on neurons, encouraging the formation of still more inactive GRK2 aggregates. As more amyloid beta accumulates, cellular stress rises; as stress increases, more GRK2 becomes inactive and forms clumps. This cycle may drive continuing nerve cell loss.
How Compound 10 Interrupts the Cycle
To stop this cycle, the researchers developed and tested a series of experimental compounds in cell cultures and mice. Compound 10 emerged as the most promising candidate. The molecule prevented inactive GRK2 from clumping together, helping preserve mitochondrial function and reducing amyloid beta accumulation in treated cells.
Mice given the compound survived longer than untreated animals and showed less nerve-cell loss.
Effects Beyond the Brain
Mice treated with Compound 10 also showed improved cardiac function and developed fewer gray hairs in old age. GRK2 is active in many parts of the body, including the heart, so its misbehavior in dementia may be part of a broader pattern of cellular dysfunction. Whether blocking GRK2 aggregation might eventually offer benefits beyond the brain remains speculative at this stage, but the mouse data makes the question worth investigating.
Where This Fits Among Current Alzheimer’s Treatments
Alzheimer’s disease is the most common cause of dementia. Current treatments do not cure the disease but may slow its progression for some patients. Cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine can help manage some symptoms, while two newer drugs — lecanemab and donanemab — have received FDA approval for slowing progression in people with early-stage disease by clearing amyloid beta from the brain. Both are associated with side effects including brain swelling and microbleeds and are approved only for patients in the earliest stages.
Compound 10 works through a different mechanism. As Quitterer noted in the ETH Zurich release, identifying GRK2 as a new target, along with an active ingredient that operates via a different mechanism than existing Alzheimer’s drugs, opens the possibility that Compound 10 could one day complement rather than replace current therapies — targeting energy failure and protein clumping upstream from where existing drugs intervene.
A drug that acts on mitochondrial dysfunction rather than amyloid clearance could in principle reach patients who do not qualify for or do not tolerate amyloid-targeting therapies.
For further reading on how lifestyle and clinical factors intersect with Alzheimer’s risk and progression, see early Alzheimer’s and brain-health metrics.
What Still Needs to Happen
ETH Zurich has filed a patent application for Compound 10 and is seeking a company to help take the next steps toward drug development. Filing a patent and finding a development partner are the earliest stages of a process that typically involves toxicology studies, dose-finding trials, and eventually multi-phase clinical trials in humans — a sequence that can take a decade or more.
The mouse results also need to be interpreted carefully. Animals develop a disease resembling human Alzheimer’s through genetic modification, and the human version involves far greater biological complexity, more genetic diversity, and decades of cumulative damage before symptoms appear. A treatment that slows neurodegeneration in engineered mice may behave entirely differently in a human brain.
The researchers connected findings in human brain tissue — those original samples from Cairo — with laboratory experiments in cells and then with mouse models. That layered approach gives the underlying mechanism more credibility than a finding from any single type of experiment alone.
Read More: An Alzheimer’s Patient Recovered Speech and Memory After One Dose of This Experimental Drug
What This Means for You
Compound 10 is not a treatment you can ask your doctor about today. It has not entered human clinical trials, and there is no timeline yet for when or whether that will happen. The research represents a new direction: a drug candidate that targets an enzyme most people have never heard of, working on the energy systems of brain cells rather than clearing protein deposits after they have already formed.
For anyone currently managing an Alzheimer’s diagnosis — their own or a family member’s — the practical picture is shaped by what is available now. As of mid-2026, lecanemab and donanemab have received FDA approval for slowing Alzheimer’s progression in people with early-stage disease and confirmed amyloid buildup. Asking a neurologist whether those drugs are appropriate is the most concrete step available for people in the early stages.
GRK2 aggregation, mitochondrial blockage, and the feedback loop that amplifies amyloid production are now documented phenomena in both human tissue and animal models. Every confirmed mechanism of damage is a potential target for future therapies. Whether Compound 10 eventually becomes a medicine will depend on years of additional research, but identifying the target with this level of precision is the necessary first step.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.